Shield TherapeuticsSTU:1JS Cyclically Adjusted PS Ratio is 1.70 as of Jul. 07, 2026, which is 68% above its 10-year median of 1.01. The stock has 5 warning signs investors should review. Among 750 Drug Manufacturers companies, Shield Therapeutics ranks better than 57.2% on this metric.
The historical rank and industry rank for Shield Therapeutics's Cyclically Adjusted PS Ratio or its related term are showing as below:
STU:1JS'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.34 Med: 1.01 Max: 3.05
Current: 1.64
During the past 12 years, Shield Therapeutics's highest Cyclically Adjusted PS Ratio was 3.05. The lowest was 0.34. And the median was 1.01.
STU:1JS's Cyclically Adjusted PS Ratio is ranked better than 57.2% of 750
companies
in the Drug Manufacturers industry
Industry Median: 2.02
vs STU:1JS: 1.64
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Shield Therapeutics's adjusted revenue per share data of for the fiscal year that ended in Dec25 was €0.041. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €0.04 for the trailing ten years ended in Dec25.
Shiller PE for Stocks: The True Measure of Stock Valuation
Shield Therapeutics (STU:1JS) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Shield Therapeutics Cyclically Adjusted PS Ratio Related Terms
Shield Therapeutics Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Shield Therapeutics's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shield Therapeutics Cyclically Adjusted PS Ratio Chart
STU:1JS vs ZTS, UTHR, VTRS: Cyclically Adjusted PS Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Shield Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shield Therapeutics Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shield Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Shield Therapeutics's Cyclically Adjusted PS Ratio falls into.
Shield Therapeutics Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Shield Therapeutics's Cyclically Adjusted PS Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 1.70 mean?
Shield Therapeutics (STU:1JS) has a Cyclically Adjusted PS Ratio of 1.70 as of Jul. 07, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Shield Therapeutics and its competitors. This is 68% above median its historical median of 1.01. Over the past decade, Shield Therapeutics' Cyclically Adjusted PS Ratio has ranged from 0.34 to 3.05. According to the industry distribution chart, Shield Therapeutics ranks #321 out of 750 companies in the Drug Manufacturers industry, placing it in the top 42.8%.
Is Shield Therapeutics' Cyclically Adjusted PS Ratio too high?
Shield Therapeutics' current Cyclically Adjusted PS Ratio of 1.70 is 68% above median its 10-year median of 1.01. Over the past 10 years, this metric has ranged from a low of 0.34 to a high of 3.05. The Drug Manufacturers industry median Cyclically Adjusted PS Ratio is 2.02. Shield Therapeutics' value of 1.70 is 15.8% below this industry median. Based on the distribution chart, Shield Therapeutics ranks #321 out of 750 companies in the Drug Manufacturers industry, which is above the industry midpoint.
How does Shield Therapeutics' Cyclically Adjusted PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Shield Therapeutics ranks #321 out of 750 companies for Cyclically Adjusted PS Ratio. This puts Shield Therapeutics in the upper half of its industry. The industry median Cyclically Adjusted PS Ratio is 2.02. Shield Therapeutics' value of 1.70 is 15.8% below this benchmark. Historically, Shield Therapeutics' own Cyclically Adjusted PS Ratio has ranged from 0.34 to 3.05 over the past decade. While the company's 10-year median is 1.01 vs. the industry median of 2.02, Shield Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Drug Manufacturers company?
The median Cyclically Adjusted PS Ratio among Drug Manufacturers companies is 2.02, based on 750 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shield Therapeutics's current Cyclically Adjusted PS Ratio of 1.70 is 15.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Shield Therapeutics and its competitors. For the Drug Manufacturers industry, the median Cyclically Adjusted PS Ratio is 2.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shield Therapeutics's current Cyclically Adjusted PS Ratio is 1.70, which is 68% above median its own 10-year median of 1.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shield Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Shield Therapeutics (STU:1JS) is currently considered Possible Value Trap. The stock's GF Value™ is €0.10, compared to a current price of €0.07 — trading 32% below its estimated fair value. The current Cyclically Adjusted PS Ratio is 1.70, which is 68% above median its 10-year median of 1.01 and 15.8% below the Drug Manufacturers industry median of 2.02. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Shield Therapeutics (STU:1JS), the current Cyclically Adjusted PS Ratio is 1.70 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Shield Therapeutics PLC is a commercial-stage specialty pharmaceutical company that delivers ACCRUFeR/FeRACCRU (ferric maltol), a differentiated pharmaceutical product, to address the unmet need for patients suffering from iron deficiency, with or without anemia. The company has launched ACCRUFeR in the U.S. Outside of the U.S., it has licensed the rights to specialty pharmaceutical companies. FeRACCRU is commercialised in the UK, the European Union, and Canada, with marketing rights in Australia and New Zealand. The company's operating segments are: FeRACCRU, which generates the maximum revenue, and PT20. Geographically, it generates maximum revenue from the U.S., and the rest from the Netherlands, Canada, Japan, and South Korea.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:1JS has been successfully added to your 